

niversité

Inserm

## Optimal design for trials with discrete longitudinal studies, with uncertainty on model and parameters

France Mentré, Florence Loingeville, Marie Karelle Rivière, Thu Thuy Nguyen

# INSERM and University Paris Diderot EMA, London – March 30, 2017



FP7 HEALTH 2013 - 602552

# **DESIGNS IN NLMEM**

- Several methods/software for maximum likelihood estimation in Non Linear Mixed Effects Models (NLMEM) for analysis of longitudinal continuous or discrete data
- Problem beforehand: choice of design
  - get precise estimates / adequate power
    - number of individuals?
    - number of sampling times/ individuals?
    - sampling times?
    - other design variables (doses, etc...)
  - Simulation (CTS): time consuming

Asymptotic theory: expected Fisher Information Matrix (Mentré, Mallet, Baccar, *Biometrika*, 1997)

### **Evaluation of Fisher matrix for discrete and time to event longitudinal data**

- Computation of the FIM for NLMEM for continuous or discrete longitudinal data without linearization of the model
  - 1. Using Monte Carlo and Hamiltonian Monte Carlo (HMC) (Rivière, Ueckert, Mentré, *Biostatistics*, 2016)
  - 2. Using Monte Carlo and Adaptive Gaussian Procedure (Ueckert, Mentré, *CSDA*, 2017)

- Both methods evaluated and compared to CTS
  - 4 data types: continuous, binary, **count**, time to event

# **Extension for robust designs in NLMEM with discrete data**

- Optimal design depends on knowledge on model and parameters
  - Local planification: model and a priori values for parameter are given
  - Widely used criterion: D-optimality (determinant of FIM)

#### • Alternative: Robust designs

- Take into account uncertainty on parameters (prior distribution)
- Over a set of candidate models (as in MCP-MOD)
- Using HMC in Stan



# Application to robust designs for repeated count data

- Exemple: Daily count of events that we want to prevent
- Poisson model for repeated count response  $P(y = k|b) = \frac{\lambda^k e^{-\lambda}}{k!}$
- Each patient observed at 3 dose levels (one placebo) during x days



- Several candidate models for the link between  $log(\lambda)$  and dose
- λ: mean number of events / day

#### Five models of effect of dose on decreasing Poisson parameter



### **Design optimisation**

Methods							
Constraints	Number of subjects	N = 60					
	Number of days	n = 10 days / dose					
	Number of doses	3 doses / patients					
	Choice of doses	$d_1 = 0$ (placebo) $d_2$ , $d_3$ from 0.1 to 1 (step 0.1, no replication)					
Combinatorial Optimization	Evaluation of FIM for all possible designs	5000 MC 200 HMC					
	For each model	DE-criterion on robust FIM (averaging for uncertainty on parameters)					
	Over 5 models	Compound DE-criterion (averaging for uncertainty on models and parameters)					

### **Results: robust optimal design for each model**



### **Results: loss of efficiency if wrong model**

	M1 Full Emax	M2 Linear	M3 Log-Linear	M4 Emax	M5 Quadratic
ξ <sub>M1</sub> =(0,0.2,0.4)	100%	47%	57%	78%	24%
ξ <sub>M2</sub> =(0,0.9,1)	73%	100%	100%	44%	87%
ξ <sub>M3</sub> =(0,0.9,1)	73%	100%	100%	44%	87%
ξ <sub>M4</sub> =(0,0.1,0.7)	89%	68%	74%	100%	51%
ξ <sub>M5</sub> =(0,0.5,1)	83%	88%	90%	59%	100%
ξ <sub>all</sub> =(0,0.2,1)	91%	84%	84%	85%	83%

Efficiency greater than 80% for all models

တ



Optimal design over 5 models  $\xi_{all}=(0,0.2,1)$ 

### **Discussion**

#### Example on count data

- Important loss of efficiency when the model is not correctly prespecified
- Good performance of the compound DE-optimal design (robust on parameters and models)

#### New methods for Robust designs

- Extension of R package *MIXFIM* to compute the robust FIM using HMC (connexion with Rstan)
- Compound optimality criterion to combine several candidate models

#### Perspectives

- Model based adaptive optimal designs (MBAOD)
- With or without uncertainty during first cohort(s)

Design trials where analysis of longitudinal data is pre-specified



## **Model parameters**

	Prior guess: ψ*				A priori distribution: p(ψ)					
	µ1*	µ2*	μ <sub>3</sub> *	ω1*	ω2*	μ <sub>1</sub>	μ <sub>2</sub>	μ <sub>3</sub>	ω <sub>1</sub>	ω <sub>2</sub>
M1	1	0.5		0.3	0.3	1	LN(-0.89,0.63)		0.3	LN(-1.50,0.77)
M2	1	0.67		0.3	0.3	1	LN(-0.60,0.63)		0.3	LN(-1.50,0.77)
M3	1	0.96		0.3	0.3	1	LN(-0.24,0.63)		0.3	LN(-1.50,0.77)
M4	1	0.2	0.8	0.3	0.3	1	LN(-1.81,0.63)	0.8	0.3	LN(-1.50,0.77)
M5	1	0.8	0.13	0.3	0.3	1	LN(-0.60,0.63)	0.13	0.3	LN(-1.50,0.77)

E(μ<sub>2</sub>)=μ<sub>2</sub>\*; E(ω<sub>2</sub>)= ω<sub>2</sub>\* CV(μ<sub>2</sub>)=70%; CV(ω<sub>2</sub>)=90%

# Using MCMC for robust designs in NLMEM

#### Robustness w.r.t. a set of *M* candidate models

• D-criterion for optimization of design  $\Xi_{D,m}$ 

 $\Phi_{D,m}(\Xi) = \det \left( \mathsf{M}(\psi_m^*, \Xi) \right)^{1/P_m}$ 

 $P_m$ : number of population parameters of model m

Compound D-criterion<sup>1,2</sup> for common optimal design Ξ<sub>CD</sub>

$$\Phi_{_{CD}}(\Xi) = \prod_{m=1}^{M} \Phi_{D,m}(\Xi)^{\alpha_m}$$

 $\alpha_m$ : weight quantifying the balance between the *M* models:  $\sum_m \alpha_m = 1$ 

#### **Robustness w.r.t. parameters and models**

Compound DE-criterion for common optimal design Ξ<sub>CDE</sub>

$$\Phi_{CDE}(\Xi) = \prod_{m=1}^{M} \Phi_{DE,m}(\Xi)^{\alpha_{m}}$$

 $\Phi_{DE,m}$ : DE-criterion evaluated for each model *m* 



<sup>1</sup> Atkinson et al. *J Stat Plan Inference*, 2008. <sup>2</sup> Nguyen et al. *Pharm Stat*, 2016.